Usha Malhotra

机构：Merck & Co., Inc., Rahway, NJ, USA (United States) · ORCID：0009-0003-3184-9605

发表论文 16 篇 · 总被引 14 次 · h-index 1

代表论文

Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: The phase 3 keynote-937 study. (2026 · Journal of Clinical Oncology · 被引 13)
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study (2026 · Cancer Research Communications · 被引 1)
Economic Burden of Recurrence in Early-Stage Hepatocellular Carcinoma Treated with Surgical Resection or Local Ablation in the United States: A Retrospective Analysis of Surveillance, Epidemiology and End Results–Medicare Data (2026 · Advances in Therapy)
Recurrence-free survival as a predictor of overall survival among patients with early-stage hepatocellular carcinoma treated with surgical resection or local ablation (2026 · Surgical Oncology Insight)
Data from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study (2026)
Table S4 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study (2026)